CHEST 2022. Tezepelumab significantly reduced AAER and improved lung function in patients taking 1, 2, or ≥3 long-acting β-agonists in addition to ICS.
The noninvasive, easily administered tool was able to predict at age 3 years children who would be diagnosed with asthma at age 5 years.
Additional research into tailored metered-dose inhaler education is needed, according to authors of a recent study.
When asthma and COPD patients have a continuous relationship with a single provider, ED visits/hospitalizations go down, survival goes up, finds a new systematic review.
New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.
Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.
ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.
ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.